Vivoryon Therapeutics AG is a biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”).
Headquartered in Halle, Germany, the company was founded in 1997 as Probiodrug by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins.
Today Vivoryon’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients. Vivoryon has identified a new therapeutic concept linked to disease initiation and progression.
The developmental approaches target pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.